Video

The Importance of Curiosity in Expanding Cancer Immunology

Jill O'Donnell-Tormey, PhD, chief executive officer, director of scientific affairs, Cancer Research Institute, discusses the importance of curiosity in expanding the role of immunology in the treatment of cancer.

Jill O’Donnell-Tormey, PhD, chief executive officer, director of scientific affairs, Cancer Research Institute, discusses the importance of curiosity in expanding the role of immunology in the treatment of patients with cancer.

It may be best from a scientific perspective to just ask great questions, have a curious mind, and follow new paths, O’Donnell-Tormey says. It is also important for researchers to not focus on what direction their work is going in, because science doesn’t necessarily work that way. James P. Allison, PhD, who was awarded a 2018 Nobel Prize in Physiology or Medicine along with Tasuku Honjo, MD, PhD, said in his acceptance speech that if he was trying to find a cure for cancer, he probably would not have discovered CTLA-4 as an immune checkpoint.

Researchers also need to understand that science takes time, persistence, and the ability to learn from failure. The field of immunotherapy is at a point now where oncologists can look at patient samples and figure out why immune resistance occurs. The lab is not the only place where research can be conducted, she concluded.

Related Videos
Alan Tan, MD, genitourinary oncology and melanoma specialist, Vanderbilt-Ingram Cancer Center; associate professor, medicine, Division of Hematology Oncology, Vanderbilt University Medical Center
Zosia Piotrowska, MD, MHS, instructor, Harvard Medical School; medical oncologist, Massachusetts General Hospital
Bartosz Chmielowski, MD
Raza Hoda, MD, FASCP
Armin Ghobadi, MD, professor, medicine, Oncology, Section of Bone Marrow Transplant; clinical director, Center for Gene and Cellular Immunotherapy, Siteman Cancer Center, Washington University
Timothy S. Fenske, MD, MS
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Roxana S. Dronca, MD, discusses the FDA’s approval of subcutaneous nivolumab across solid tumor indications.
Craig Eckfeldt, MD
Whitney Goldsberry, MD